Medicines on the FDA drug shortage list, with which forms and strengths are affected, who makes them and when supply is expected back.
161 medicines
-
Epinephrine Being discontinued 2 products · updated November 7, 2025
Cardiovascular, Endocrinology/Metabolism
Product Availability Expected supply / notes Epinephrine, Injection, .1 mg/1 mL (NDC 0409-4933-01)
Hospira, Inc., a Pfizer CompanyDiscontinuation of the manufacture of the drug
Being discontinued · November 7, 2025Epinephrine, Injection, .1 mg/1 mL (NDC 0409-4933-10)
Hospira, Inc., a Pfizer CompanyDiscontinuation of the manufacture of the drug
Being discontinued · November 7, 2025 -
Ketamine Hydrochloride Being discontinued 1 product · updated November 7, 2025
Anesthesia
Product Availability Expected supply / notes Ketamine Hydrochloride, Injection, 500 mg/5mL (100 mg/mL); Multiple Dose Glass Fliptop Vial Novaplus (NDC 0409-0040-10)
Pfizer Inc.Discontinuation of the manufacture of the drug
Being discontinued · November 7, 2025 -
Lidocaine Hydrochloride Being discontinued 2 products · updated November 7, 2025
Anesthesia, Pediatric, Analgesia/Addiction
Product Availability Expected supply / notes Lidocaine Hydrochloride, Injection, 1%, USP (For Cardiac Use Only) 50 mg/5 mL (10 mg/mL) LifeShield™ ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4904-34)"
Hospira, Inc., a Pfizer CompanyDiscontinuation of the manufacture of the drug
Being discontinued · November 7, 2025Lidocaine Hydrochloride, Injection, 2%, USP (For Cardiac Use Only) 100 mg/5 mL (20 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4903-34)"
Hospira, Inc., a Pfizer CompanyDiscontinuation of the manufacture of the drug
Being discontinued · November 7, 2025 -
Sodium Bicarbonate Being discontinued 4 products · updated November 7, 2025
Endocrinology/Metabolism, Gastroenterology, Pediatric
Product Availability Expected supply / notes Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 0409-4900-14)
Hospira, Inc., a Pfizer CompanyDiscontinuation of the manufacture of the drug
Being discontinued · November 7, 2025Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 0409-5534-14)
Hospira, Inc., a Pfizer CompanyDiscontinuation of the manufacture of the drug
Being discontinued · November 7, 2025Sodium Bicarbonate, Injection, 75 mg/1 mL (NDC 0409-4916-14)
Hospira, Inc., a Pfizer CompanyDiscontinuation of the manufacture of the drug
Being discontinued · November 7, 2025Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 0409-6637-14)
Hospira, Inc., a Pfizer CompanyDiscontinuation of the manufacture of the drug
Being discontinued · November 7, 2025 -
Acetaminophen; Oxycodone Hydrochloride Being discontinued 1 product · updated November 3, 2025
Analgesia/Addiction
Product Availability Expected supply / notes Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 2.5 mg (NDC 63481-627-70)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · November 3, 2025 -
Atazanavir and Cobicistat Being discontinued 1 product · updated November 3, 2025
Antiviral
Product Availability Expected supply / notes Evotaz, Tablet, 300 mg; 150 mg (NDC 0003-3641-11)
Bristol Myers Squibb Co.The global Cease Manufacture date for EVOTAZ® currently is estimated to begin April 2026.
Being discontinued · November 3, 2025 -
Lasmiditan Being discontinued 6 products · updated November 3, 2025
Neurology
Product Availability Expected supply / notes Reyvow, Tablet, 50 mg (NDC 0002-4312-62)
Eli Lilly and Co.A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.
Being discontinued · November 3, 2025Reyvow, Tablet, 100 mg (NDC 0002-4491-62)
Eli Lilly and Co.A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.
Being discontinued · November 3, 2025Reyvow, Tablet, 50 mg (NDC 0002-4312-61)
Eli Lilly and Co.A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.
Being discontinued · November 3, 2025Reyvow, Tablet, 100 mg (NDC 0002-4491-08)
Eli Lilly and Co.A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.
Being discontinued · November 3, 2025Reyvow, Tablet, 50 mg (NDC 0002-4312-08)
Eli Lilly and Co.A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.
Being discontinued · November 3, 2025Reyvow, Tablet, 100 mg (NDC 0002-4491-61)
Eli Lilly and Co.A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.
Being discontinued · November 3, 2025 -
Oxycodone and Acetaminophen Being discontinued 5 products · updated November 3, 2025
Analgesia/Addiction
Product Availability Expected supply / notes Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 2.5 mg (NDC 60951-701-70)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · November 3, 2025Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 7.5 mg (NDC 60951-700-70)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · November 3, 2025Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 5 mg (NDC 60951-602-70)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · November 3, 2025Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 10 mg (NDC 60951-712-70)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · November 3, 2025Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 5 mg (NDC 60951-602-85)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · November 3, 2025 -
Scopolamine Transdermal System Being discontinued 1 product · updated November 3, 2025
Gastroenterology, Neurology, Other
Product Availability Expected supply / notes Scopolamine, Transdermal System, 1 mg (NDC 45802-580-46)
Padagis US LLCDiscontinuation of the manufacture of the drug
Being discontinued · November 3, 2025 -
Phenobarbital Being discontinued 8 products · updated October 31, 2025
Analgesia/Addiction, Neurology, Other
Product Availability Expected supply / notes Phenobarbital, Tablet, 97.2 mg (NDC 0603-5168-32)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · October 31, 2025Phenobarbital, Tablet, 16.2 mg (NDC 0603-5165-21)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · October 31, 2025Phenobarbital, Tablet, 64.8 mg (NDC 0603-5167-21)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · October 31, 2025Phenobarbital, Tablet, 32.4 mg (NDC 0603-5166-21)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · October 31, 2025Phenobarbital, Tablet, 64.8 mg (NDC 0603-5167-32)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · October 31, 2025Phenobarbital, Tablet, 32.4 mg (NDC 0603-5166-32)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · October 31, 2025Phenobarbital, Tablet, 97.2 mg (NDC 0603-5168-21)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · October 31, 2025Phenobarbital, Tablet, 16.2 mg (NDC 0603-5165-32)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · October 31, 2025 -
Prazosin Hydrochloride Being discontinued 3 products · updated April 28, 2023
Cardiovascular
Product Availability Expected supply / notes Minipress, Capsule, 2 mg (NDC 0069-4370-71)
Pfizer Inc.Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023
Being discontinued · April 28, 2023Minipress, Capsule, 1 mg (NDC 0069-4310-71)
Pfizer Inc.Discontinuation of the manufacture of the drug. Supply expected to exhaust in August 2023
Being discontinued · April 28, 2023Minipress, Capsule, 5 mg (NDC 0069-4380-71)
Pfizer Inc.Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023
Being discontinued · April 28, 2023
Reading the list: a medicine stays on the FDA list while any of its products is short. "Available" next to a product means that particular strength or pack can currently be ordered. If your pharmacy cannot fill a prescription, ask the pharmacist or prescriber about another strength, form or an alternative — do not ration or stop a medicine on your own.
Source: FDA Drug Shortages Database, via openFDA. Updated here twice a day; last update November 1, 2026 02:40. openFDA data are not validated for clinical use — confirm with the FDA source or your pharmacist.